Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 11/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.36 |
| ▸ | LCK | P06239 | 4/20 | 0.34 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 5/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30171732 | 1.00 | PTK6 (0.40) | PTK6AURKBLCKMAPKAPK5TTK | |
| SCHEMBL22124668 | 0.95 | PTK6 (0.38) | PTK6AURKBLCKMAPKAPK5TTK | |
| SCHEMBL22124465 | 0.94 | PTK6 (0.41) | PTK6AURKBLCKMAPKAPK5TTK | |
| SCHEMBL22122882 | 0.93 | PTK6 (0.39) | PTK6AURKBLCKMAPKAPK5TTK | |
| SCHEMBL22123102 | 0.92 | PTK6 (0.38) | PTK6AURKBLCKMAPKAPK5TTK | |
| SCHEMBL22125143 | 0.92 | PTK6 (0.38) | PTK6AURKBLCKMAPKAPK5TTK | |
| SCHEMBL30349825 | 0.92 | PTK6 (0.38) | PTK6AURKBLCKMAPKAPK5TTK | |
| SCHEMBL22122833 | 0.92 | PTK6 (0.38) | PTK6AURKBLCKMAPKAPK5TTK | |
| SCHEMBL30183424 | 0.92 | PTK6 (0.38) | PTK6AURKBLCKMAPKAPK5TTK | |
| SCHEMBL22123447 | 0.91 | PTK6 (0.38) | PTK6AURKBLCKMAPKAPK5TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898631-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | claimed |
| WO-2020126953-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | claimed |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| EP-3898631-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020126953-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, MYD88, IL1R1 | PTK6 2211/4885AURKB 3359/4885LCK 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.